latentbrief
← Back to editorials

Editorial · Product Launch

Why Healthcare AI Is Struggling to Get Off the Ground - And What Needs to Change

1w ago

The promise of artificial intelligence revolutionizing healthcare has been a refrain for years. But as the industry stands today, that promise remains largely unfulfilled. The reality is stark: building AI for healthcare is proving to be an economic black hole for startups, with little return on massive investments despite clinical validation and market demand.

Kintsugi’s recent shutdown after seven years and $30 million in funding serves as a glaring example of the systemic challenges plaguing the sector. The company developed groundbreaking voice biomarkers capable of detecting depression and anxiety-a solution that could have made mental healthcare more accessible globally. Yet, faced with the insurmountable pressures of venture timelines and regulatory hurdles, they were forced to abandon their mission.

The crux lies in the structural mismatch between the rapid pace of AI innovation and the slow-moving world of healthcare regulation. While startups are expected by investors to achieve $100 million in annual recurring revenue within a handful of years, the reality is far different. Regulatory clearance-a prerequisite for commercial success-takes years to secure. This creates an untenable environment where companies struggle to meet both investor expectations and regulatory demands.

The financial burden compounds further when considering the costs associated with clinical trials and research. Kintsugi’s pivotal study alone involved 1,600 participants over four years-a level of investment that is difficult to justify in a funding climate increasingly hostile to healthcare AI startups. With mental health AI companies facing intense scrutiny over efficacy and compliance, many are forced to pivot or shut down entirely.

The broader industry data reflects this grim reality. Healthcare AI shutdowns rose by over 25% between 2024 and 2025 amidst a funding contraction. Only about 16% of mental health AI tools have undergone rigorous clinical testing-a figure that raises serious concerns among regulators. The Illinois legislature’s prohibition on AI in therapy services further underscores the growing skepticism toward these technologies.

The situation is compounded by investor expectations that often clash with the mission-driven objectives of healthcare startups. When Kintsugi considered pivoting to security applications, it only succeeded in confusing investors and complicating fundraising efforts. This illustrates how rigid investor demands can strangle innovation even when alternative opportunities exist.

A meaningful shift will require rethinking the metrics used to evaluate healthcare AI companies. Investors must align their timelines with the realities of regulatory clearance and clinical validation. Policymakers need to establish clearer guidelines that prioritize patient safety without stifling innovation. And startups must adopt more sustainable business models-whether through public-private partnerships, open-source initiatives, or alternative revenue streams.

The potential benefits of AI in healthcare are immense, from improving diagnostics to enhancing mental health support. But realizing this vision demands a reimagined approach-one where the drive for innovation is matched by thoughtful consideration of the challenges involved. Until these structural issues are addressed, the promise of AI in healthcare will remain elusive.

Editorial perspective — synthesised analysis, not factual reporting.

Terms in this editorial

Kintsugi
A company that developed voice biomarkers to detect mental health conditions like depression and anxiety, which could make mental healthcare more accessible globally. Unfortunately, they had to shut down due to challenges with venture timelines and regulatory hurdles.

If you liked this

More editorials.